Correlação entre ciclina D-1, receptores de estrogênio e progesterona no carcinoma invasivo de mama após curto período de endocrinoterapia com tamoxifeno e anastrozol
Nenhuma Miniatura disponível
Arquivos
Data
2009
Autores
Millen, Eduardo Camargo [UNIFESP]
Orientadores
Gebrim, Luiz Henrique [UNIFESP]
Tipo
Tese de doutorado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Introdução: A endocrinoterapia é uma das principais responsáveis pela redução da mortalidade do câncer de mama. Biomarcadores preditivos de resposta celular precoce vem sendo estudados com intuito de prever precocemente a hormônio-resistência. A positividade dos receptores de estrogênio e progesterona e a ciclina D-1 vem sendo relacionados à resistência ao tratamento com tamoxifeno. Objetivos: Estudar a variação da ciclina D-1 e os receptores de estrogênio e progesterona (RE e RP) em pacientes na pós-menopausa com carcinoma de mama RE e ou RP (+) após curto período (26 dias) de tratamento com tamoxifeno, anastrozol e placebo. Métodos: Estudo prospectivo randomizado duplo-cego realizado com 71 pacientes dos Hospitais Pérola Byington e São Paulo da UNIFESP (São Paulo - Brasil) com carcinoma ductal infiltrativo de mama, nos estádios II e III, que no período pré-operatório (26 dias) foram subdivididas em 3 grupos: P (placebo, N= 26) T (tamoxifeno 20mg/dia, N= 22) e A (anastrozol, 1mg/dia N = 23). A biópsia foi realizada no momento do diagnóstico, e após a cirurgia definitiva (26º dia) os tumores foram isolados por micro-arranjos teciduais. O estudo imunoistoquímico foi realizado com anticorpos para ciclina D-1 (Novocastra DCS-6), RE (Dako- M7047), RP (Dako- M3569). Realizou-se o estudo semiquantitativo utilizando-se os critérios de Allred e o estudo estatístico pelo teste paramétrico de Anova e semi-paramétrico General Estimation Equation (p≤0,05). Resultados: Houve redução da média do escore do RP de 4,22 (pré) para 1,94 (pós) apenas nas pacientes tratadas com anastrozol (p= 0,01). Houve correlação linear positiva entre ciclina D-1 e RP no grupo A (p<0,001), negativa no T (p<0,001) sem variar no grupo Placebo (p = 0,35). Conclusão: É possível que RP e ciclina D-1 possam ser bons fatores preditivos de resposta precoce para inibidores de aromatase do câncer de mama..
Background: Hormone Therapy (HT) plays an important role in breast cancer mortality reduction. Predictive biomarkers of early cellular response have being studied with the intention to predict the hormone resistance. The positivity of cyclin D1, estrogen and progesterone receptors (ER/PR) is being related to the resistance to the tamoxifen treatment. Objectives: Study the variation of the cyclin D-1, ER and PR in postmenopausal patients with ER positive invasive ductal carcinomas (IDC) prior and after short period (26 days) of treatment with tamoxifen, anastrozole and placebo. Methods: Seventy-one patients with palpable ER-positive IDC (stage II and III) were double-blind randomized in a prospective placebo controlled trial with 3 neoadjuvant HT groups in the pre operatory phase (26 days): P (placebo, N= 26) T (tamoxifen 20mg/day, N= 22) and (anastrozole, 1mg/day N = 23). Pre and post HT samples were disposed in tissue micro array blocks and submitted to immunohistochemical assay. Biomarkers status (cyclin D- 1, ER and PR) was obtained comparing each immunohistochemical evaluation of pre and post-surgery samples using semi-quantitative Allred’s method. Statistical analyses were performed using the parametric test of Anova and semiparametric test General Estimation Equation (p ≤ 0,05). Results: There was a reduction in Allred’s PR score from 4.22 (pre-treatment) to 1.94 (post-treatment) only in patients treated with anastrozole (p=0,01). There was a linear positive correlation between cyclin D-1 and PR in the group A (p< 0.001), negative in the T (p< 0,001) without varying in the placebo group (p = 0,35). Conclusion: It is possible that PR and cyclin D-1 would be a good predictor of early response for aromatase inhibitors in breast cancer.
Background: Hormone Therapy (HT) plays an important role in breast cancer mortality reduction. Predictive biomarkers of early cellular response have being studied with the intention to predict the hormone resistance. The positivity of cyclin D1, estrogen and progesterone receptors (ER/PR) is being related to the resistance to the tamoxifen treatment. Objectives: Study the variation of the cyclin D-1, ER and PR in postmenopausal patients with ER positive invasive ductal carcinomas (IDC) prior and after short period (26 days) of treatment with tamoxifen, anastrozole and placebo. Methods: Seventy-one patients with palpable ER-positive IDC (stage II and III) were double-blind randomized in a prospective placebo controlled trial with 3 neoadjuvant HT groups in the pre operatory phase (26 days): P (placebo, N= 26) T (tamoxifen 20mg/day, N= 22) and (anastrozole, 1mg/day N = 23). Pre and post HT samples were disposed in tissue micro array blocks and submitted to immunohistochemical assay. Biomarkers status (cyclin D- 1, ER and PR) was obtained comparing each immunohistochemical evaluation of pre and post-surgery samples using semi-quantitative Allred’s method. Statistical analyses were performed using the parametric test of Anova and semiparametric test General Estimation Equation (p ≤ 0,05). Results: There was a reduction in Allred’s PR score from 4.22 (pre-treatment) to 1.94 (post-treatment) only in patients treated with anastrozole (p=0,01). There was a linear positive correlation between cyclin D-1 and PR in the group A (p< 0.001), negative in the T (p< 0,001) without varying in the placebo group (p = 0,35). Conclusion: It is possible that PR and cyclin D-1 would be a good predictor of early response for aromatase inhibitors in breast cancer.
Descrição
Citação
MILLEN, Eduardo Camargo. Correlação entre ciclina D-1, receptores de estrogênio e progesterona no carcinoma invasivo de mama após curto período de endocrinoterapia com tamoxifeno e anastrozol. 2009.
75 f. Tese (Doutorado em Ciências) – Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2009.